Abstract Treatment for inflammatory bowel disease (IBD) is challenging since current anti-
inflammatory and immunosuppressive therapies do not address the underlying causes of …

Inflammatory bowel diseases (IBDs) refer to multifaceted disorders in the intestinal
microenvironment and microbiota homeostasis. In view of the broad bioactivity and high …

Introduction: Inflammatory bowel disease (IBD) affects about 7 million people globally, which
is a chronic inflammatory condition of the gastrointestinal tract caused by gut microbiota …

Abstract Herein, a β-1, 3-D-glucan based yeast cell wall loaded with co-loaded
nanoparticles of Rhein (RH) and Emodin (EMO), was developed for the combined treatment …

Intestinal immune dysfunction and gut microbiota dysbiosis are critically causative factors in
the pathogenesis of ulcerative colitis (UC); however, the current first-line drugs for UC …

Inflammatory bowel disease (IBD) is a refractory disorder characterized by chronic and
recurrent inflammation. The progression and pathogenesis of IBD is closely related to …

Dysfunction of the intestinal mucosal immune system and dysbiosis of the intestinal
microflora can induce inflammatory bowel disease. However, drug-mediated clinical …

The gut microbiota are prominent in preserving intestinal environmental homeostasis and
managing human health, and their dysbiosis has been directly related to many kinds of …

Inflammatory bowel disease (IBD) is closely associated with dysregulated immune
response, gut mucosal barrier, and microbiota. Conventional treatments suffer from inferior …

Reactive oxygen species (ROS), immune dysregulation-induced inflammatory outbreaks
and microbial imbalance play critical roles in the development of inflammatory bowel …